Table 1.
Sensitivity of the 25 melanoma cell lines to trametinib and their mutation status
| Cell line ID | NRAS | BRAF | NF1 PROTEIN | TRAMETINIB ICI50 (nM) |
|---|---|---|---|---|
| C058 | WT | L597P | NA | 0.15 |
| M14 | WT | V600E | NA | 0.6 |
| C32 | WT | V600E | NA | 0.7 |
| HT144 | WT | V600E | NA | 1 |
| MR1010B | WT | V600E | NA | 2.5 |
| A101D | WT | V600E | NA | 3 |
| IGR1 | WT | V600E | NA | 4 |
| ISTMEL1 | WT | V600E | NA | >10 |
| C089 | WT | V600E | POSITIVE | 0.2 |
| D35 | WT | WT | POSITIVE | 0.4 |
| A04 | WT | WT | POSITIVE | 0.4 |
| C052 | WT | WT | POSITIVE | 0.5 |
| C037 | WT | Translocation | POSITIVE | 0.5 |
| D10 | WT | WT | POSITIVE | 0.6 |
| D38 | WT | WT | POSITIVE | 1.3 |
| CHL-1 | WT | WT | POSITIVE | 9 |
| Colo-792 | WT | WT | NEGATIVE | 0.4 |
| C008 | WT | WT | NEGATIVE | 0.6 |
| C067 | WT | WT | NEGATIVE | 0.7 |
| C025 | WT | WT | NEGATIVE | 0.9 |
| MeWo | WT | WT | NEGATIVE | 1 |
| C086 | WT | WT | NEGATIVE | 1.3 |
| C077 | WT | WT | NEGATIVE | 5 |
| C021 | WT | WT | NEGATIVE | 8 |
| D24 | WT | WT | NEGATIVE | 10 |
Each cell lines was treated with nine different concentrations of trametinib (range 0.08–10 nM) for 6 days, fixed and stained with Syto60. The relative viability was calculated versus the vehicle treated control. The IC50 was calculated from the dose response curve. Experiments were performed in triplicate. The mutation status was assessed by Sequenom MassArray platform. NF1 protein expression was evaluated by Western blotting, as described in Figure1. NA = not analysed. C037 cell line carries a BRAF translocation (see Data S1). See also Table S1.